[go: up one dir, main page]

WO2010142551A3 - Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family - Google Patents

Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family Download PDF

Info

Publication number
WO2010142551A3
WO2010142551A3 PCT/EP2010/057538 EP2010057538W WO2010142551A3 WO 2010142551 A3 WO2010142551 A3 WO 2010142551A3 EP 2010057538 W EP2010057538 W EP 2010057538W WO 2010142551 A3 WO2010142551 A3 WO 2010142551A3
Authority
WO
WIPO (PCT)
Prior art keywords
variable domain
single variable
vhh
cytokines
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/057538
Other languages
French (fr)
Other versions
WO2010142551A2 (en
WO2010142551A8 (en
Inventor
Anna Hultberg
Bram Maassen
Michael John Scott Saunders
Johannes Joseph Wilhelmus De Haard
Peter Vanlandschoot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of WO2010142551A2 publication Critical patent/WO2010142551A2/en
Publication of WO2010142551A8 publication Critical patent/WO2010142551A8/en
Publication of WO2010142551A3 publication Critical patent/WO2010142551A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to amino acid sequences that are directed against (as defined herein) the IL-17 receptors, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as "amino acid sequences of the invention", "immunoglobulin single variable domain of the invention", '"compounds of the invention'', and ''polypeptides of the invention", respectively).
PCT/EP2010/057538 2009-06-12 2010-05-31 Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family Ceased WO2010142551A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18658609P 2009-06-12 2009-06-12
US61/186,586 2009-06-12

Publications (3)

Publication Number Publication Date
WO2010142551A2 WO2010142551A2 (en) 2010-12-16
WO2010142551A8 WO2010142551A8 (en) 2011-04-21
WO2010142551A3 true WO2010142551A3 (en) 2011-06-16

Family

ID=42321019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/057538 Ceased WO2010142551A2 (en) 2009-06-12 2010-05-31 Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family

Country Status (1)

Country Link
WO (1) WO2010142551A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453726B2 (en) 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
UA117218C2 (en) * 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
GB201500461D0 (en) * 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022032022A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10 receptor binding molecules and methods of use
WO2022032006A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb binding molecules and methods of use
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
CN116322754A (en) 2020-08-05 2023-06-23 辛德凯因股份有限公司 IL10RA binding molecules and methods of use
WO2022032005A2 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Il10rb binding molecules and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046420A2 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
WO2006088833A2 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
WO2008054603A2 (en) * 2006-10-02 2008-05-08 Amgen Inc. Il-17 receptor a antigen binding proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046420A2 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
WO2006088833A2 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
WO2008054603A2 (en) * 2006-10-02 2008-05-08 Amgen Inc. Il-17 receptor a antigen binding proteins

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Human IL-17B R Antibody, monoclonal mouse IgG2B clone 170220, Cat No: MAB1207 & Catalog Addendum 2004", 2004, XP002592736, Retrieved from the Internet <URL:http://www.rndsystems.com/pdf/mab1207.pdf> [retrieved on 20100720] *
"Monoclonal Anti-human IL-17B R Antibody", INTERNET CITATION, 9 November 2008 (2008-11-09), pages 1 - 2, XP002592737, Retrieved from the Internet <URL:http://www.rndsystems.com> [retrieved on 20100720] *
DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL LNKD- DOI:10.1016/S1380-2933(96)00045-0, vol. 2, no. 3, 1 September 1996 (1996-09-01), pages 169 - 179, XP004070292, ISSN: 1380-2933 *
DE GENST E ET AL: "Antibody repertoire development in camelids", DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, PERGAMON PRESS, US LNKD- DOI:10.1016/J.DCI.2005.06.010, vol. 30, no. 1-2, 1 January 2006 (2006-01-01), pages 187 - 198, XP025088320, ISSN: 0145-305X, [retrieved on 20060101] *
HOLT L J ET AL: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB LNKD- DOI:10.1016/J.TIBTECH.2003.08.007, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484 - 490, XP004467495, ISSN: 0167-7799 *
RICKEL ERIKA A ET AL: "Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 181, no. 6, 1 September 2008 (2008-09-01), pages 4299 - 4310, XP002567204, ISSN: 0022-1767 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.79.6.1979, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424 *
SAERENS D ET AL: "Single-domain antibodies as building blocks for novel therapeutics", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL LNKD- DOI:10.1016/J.COPH.2008.07.006, vol. 8, no. 5, 1 October 2008 (2008-10-01), pages 600 - 608, XP025609339, ISSN: 1471-4892, [retrieved on 20080822] *
SAERENS DIRK ET AL: "Antibody technology in proteomics", BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, HENRY STEWART, LONDON, GB, vol. 7, no. 4, 1 July 2008 (2008-07-01), pages 275 - 282, XP009132895, ISSN: 1473-9550 *
VINCKE CÉCILE ET AL: "General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M806889200, vol. 284, no. 5, 30 January 2009 (2009-01-30), pages 3273 - 3284, XP009124408, ISSN: 0021-9258, [retrieved on 20081114] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453726B2 (en) 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers

Also Published As

Publication number Publication date
WO2010142551A2 (en) 2010-12-16
WO2010142551A8 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2010142551A3 (en) Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2011002968A3 (en) Polypeptides and method of treatment
EA201001223A1 (en) STABILIZED PROTEIN COMPOSITIONS
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2009112245A9 (en) Antibody against the csf-1 r
MA32982B1 (en) Binding proteins to human cgrp receptors
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
WO2011047087A3 (en) Protein detection via nanoreporters
EA201170030A1 (en) IL-6-MEDIATED IMMUNOTHERAPY
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
AU2009260320A8 (en) Antibodies to IL-6 and their uses
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2006119107A3 (en) Sclerostin binding agents
WO2006119062A3 (en) Sclerostin epitopes
WO2009068625A3 (en) Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009018126A3 (en) Collagen-related peptides and uses thereof
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10724431

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10724431

Country of ref document: EP

Kind code of ref document: A2